Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer
摘要:
In vivo phosphorylation. of FTY720 (1) in rats and humans resulted exclusively in the biologically active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol especially elaborated for phosphates of 1. Starting from the prochiral amino alcohol 1, racemic and enantiomerically pure phosphates of 1 were synthesized. Pure enantiomers were obtained after purification of a partially protected key intermediate on an enantioselective support. The absolute stereochemistry was determined by X-ray diffraction.
[EN] PHOSPHINANE COMPOUNDS WITH IMMUNOMODULATING ACTIVITY<br/>[FR] COMPOSES DE PHOSPHINANE A EFFET IMMUNOMODULATEUR
申请人:MITSUBISHI PHARMA CORP
公开号:WO2005014603A1
公开(公告)日:2005-02-17
The invention is directed to a phosphinane compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or diseases mediated by T lymphocytes by administering the compound to a subject in need of treatment.
Immunoregulatory compounds are disclosed of the formula:
1
and
2
as well as the pharmaceutically acceptable salts and hydrates thereof, are disclosed. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection.
Pharmaceutical compositions and methods of use are included.
[EN] PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS<br/>[FR] DERIVES DE PHOSPHATES UTILISES EN TANT QU'AGENTS IMMUNO-REGULATEURS
申请人:MERCK & CO INC
公开号:WO2002018395A1
公开(公告)日:2002-03-07
Immunoregulatory compounds are disclosed of the formula: and as well as the pharmaceutically acceptable salts and hydrates thereof, are disclosed. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Compounds of formula (i), wherein m, R, R
1
, and R
3
to R
6
are as defined in the specification, m, is 1, 2 or 3 and X is O or a direct bond, and the corresponding unphosporylated compounds have interesting properties, e.g. immunosuppressive properties.
1
Compounds of formula I:
wherein R
1
, R
2
, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.